Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford JuniorfiledCriticalUniv Leland Stanford Junior
Publication of AR122427A1publicationCriticalpatent/AR122427A1/en
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Peptides Or Proteins
(AREA)
Abstract
Un copolímero a base de poliacrilamida reduce o evita la agregación de proteínas y péptidos en las formulaciones acuosas en las interfaces hidrofóbicas, de este modo aumenta la estabilidad térmica de proteínas y péptidos en la formulación. Los métodos y las composiciones que comprenden el copolímero y una proteína o el copolímero e insulina se pueden usar para tratar afecciones que incluyen diabetes.A polyacrylamide-based copolymer reduces or prevents aggregation of proteins and peptides in aqueous formulations at hydrophobic interfaces, thereby increasing the thermal stability of proteins and peptides in the formulation. The methods and compositions comprising the copolymer and a protein or the copolymer and insulin can be used to treat conditions including diabetes.
ARP210101041A2020-04-172021-04-19
POLYMERIC EXCIPIENTS FOR BIOPHARMACEUTICAL FORMULATIONS
AR122427A1
(en)
IMMUNOGENIC FORMULATION, BECAUSE IT INCLUDES AN ATTENUATED RECOMBINANT STRAIN OF MYCOBACTERIUM, PREFERENTIALLY THE RECOMBINANT STRAIN BACILO DE CALMETTE AND GUERIN (BCG), WHICH EXPRESSES AT LEAST ONE PROTEIN OR RESPIRATORY IMMUNOGENIC FRAGMENT OF THE VIRUS